Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

PD-1 inhibitor plus platinum and fluorouracil

10 evidence topics · 7 sources

KEYNOTE-048 efficacy of pembrolizumab with platinum and fluorouracil at the interim analysis: overall population
EndpointPembrolizumab with platinum and FUCetuximab with platinum and FU
Participants“n=281”“n=278”
Median OS, months (95% CI)“13.0 (10.9, 14.7)”“10.7 (9.3, 11.7)”
OS hazard ratio (95% CI)“0.77 (0.63, 0.93)”Reference
Median PFS, months (95% CI)“4.9 (4.7, 6.0)”“5.1 (4.9, 6.0)”
PFS hazard ratio (95% CI)“0.92 (0.77, 1.10)”Reference
ORR (95% CI)“36% (30.0, 41.5)”“36% (30.7, 42.3)”
Median duration of response, months (range)“6.7 (1.6+, 30.4+)”“4.3 (1.2+, 27.9+)”
KEYNOTE-048 four-year follow-up: pembrolizumab with chemotherapy

“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote